TLP
MRVI icon

Tri Locum Partners’s Maravai LifeSciences MRVI Stock Holding History

Tri Locum Partners’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-280,811
Closed -$7.17M – 86
2022
Q3 		$7.17M Buy
+280,811
New +$7.05M 1.97% 19

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
OCBV
Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Tri Locum Partners's MRVI Position: Q4 2022 in Review

Tri Locum Partners sold out of Maravai LifeSciences (MRVI) in Q4 2022, closing a stake of 280,811 shares — an estimated $7.17M sold.

Tri Locum Partners first reported a position in MRVI in Q3 2022 and held it in 1 quarter. The position peaked at $7.17M in Q3 2022. 212 funds tracked by Wall St. Rank hold MRVI as of Q4 2022.

  • Tri Locum Partners reported no remaining Maravai LifeSciences position as of Q4 2022 after selling out during the quarter.
  • Tri Locum Partners sold 280,811 Maravai LifeSciences shares in Q4 2022, an estimated $7.17M.
  • Tri Locum Partners first reported a position in Maravai LifeSciences in Q3 2022 and held it in 1 quarter.
  • Tri Locum Partners's Maravai LifeSciences position peaked at $7.17M in Q3 2022.
  • 212 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q4 2022.

Based on Tri Locum Partners's 13F filing for Q4 2022, filed 14 Feb 2023.